Oral Cavity Cancer, Oropharyngeal Cancer
Conditions
Brief summary
The purpose of this study is to correlate the results from a standard of care biopsy with CytID™ and hpvID™ swab tests for potentially premalignant and malignant oral lesions. The biopsy is considered standard of care and will be performed regardless of the patient's enrollment in the study. The study-related data gathering will not influence the treatment decisions of the clinician.
Interventions
Suspicious oral lesions will be identified by oral examination with incandescent light.
OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
Tissue will be collected to identify pre-cancerous or cancerous cells
CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
Sponsors
Study design
Eligibility
Inclusion criteria
* Receive care at the Avenue 360 Health and Wellness Clinic, a not for profit dental clinic in the Montrose area of Houston * Present with a potentially malignant oral lesion (PMOL) for whom a biopsy is deemed necessary
Exclusion criteria
* Do not receive care at the Avenue 360 Health and Wellness Clinic, a not for profit dental clinic in the Montrose area of Houston * Do not present with a potentially malignant oral lesion (PMOL) for whom a biopsy is deemed necessary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants for whom biopsy and CytID results both indicate presence of malignant or premalignant oral lesions | day 1 (at the time of oral examination) |
| Number of participants for whom biopsy indicates presence of malignant or premalignant oral lesions and hpvID indicates presence of HPV | day 1 (at the time of oral examination) |
| Number of participants for whom biopsy results, but not CytID results, indicate presence of malignant or premalignant oral lesions | day 1 (at the time of oral examination) |
| Number of participants for whom CytID results, but not biopsy results, indicate presence of malignant or premalignant oral lesions | day 1 (at the time of oral examination) |
| Number of participants for whom biopsy does not indicate presence of malignant or premalignant oral lesions, but hpvID indicates presence of HPV | day 1 (at the time of oral examination) |
| Number of participants for whom biopsy indicates presence of malignant or premalignant oral lesions, but hpvID does not indicate presence of HPV | day 1 (at the time of oral examination) |
Countries
United States